Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

After a single administration of up to 380 mg by oral route, DNDI-6148 had an acceptable safety and tolerability profile and a favourable PK profile. These data support further clinical development.